The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling von Lin, L, Amin, R, Gallicano, G I, Glasgow, E, Jogunoori, W, Jessup, J M, Zasloff, M, Marshall, J L, Shetty, K, Johnson, L, Mishra, L, He, A R

Volltext

Novel curved roll contour technology for profile control in hot strip mills von He, A-R., Kong, F-F., Shao, J.

Volltext

Constitutive Model and Micro Hardening and Softening Mechanism for Nonoriented Electrical Steel von Liu, C., He, A. R., Qiang, Y., Guo, D. F., Shao, J.

Volltext

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study von Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, Lee, Kyung-Hun, Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N

Volltext

Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans von BJÖRNHOLM, M, HE, A. R, ATTERSAND, A, LAKE, S, LIU, S. C. H, LIENHARD, G. E, TAYLOR, S, ARNER, P, ZIERATH, J. R

Volltext

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040 von Melero, I., Yau, T., Kang, Y.-K., Kim, T.-Y., Santoro, A., Sangro, B., Kudo, M., Hou, M.-M., Matilla, A., Tovoli, F., Knox, J., He, A.R., El-Rayes, B., Acosta-Rivera, M., Lim, H.Y., Soleymani, S., Yao, J., Neely, J., Tschaika, M., Hsu, C., El-Khoueiry, A.B.

Volltext

Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study von Lee, K.-H., Hsu, C.-H., Lee, M.S., Ryoo, B.-Y., Verret, W., He, A.R., Kwan, A., Liu, B., Iizuka, K., Stein, S.

Volltext

Comprehensive contour prediction model of work roll used in online strip shape control model during hot rolling von Wang, X.-D., Yang, Q., He, A.-R., Wang, R.-Z.

Volltext

Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer von Shivapurkar, N., Mikhail, S., Navarro, R., Bai, W., Marshall, J., Hwang, J., Pishvaian, M., Wellstein, A., He, A. R.

Volltext

Activation of Serum- and Glucocorticoid-induced Protein Kinase (Sgk) by Cyclic AMP and Insulin von Perrotti, Nicola, He, Ruth A., Phillips, Susan A., Haft, Carol Renfrew, Taylor, Simeon I.

Volltext

Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with a... von Oh, D., He, A.R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasa, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., Valle, J.W.

Volltext

831TiPA phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary... von Oh, D-Y, Chen, L-T, He, A R, Okusaka, T, Qin, S, Chin, S, Rokutanda, N, Uchinda, H, Vogel, A, Valle, J W, Kim, H

Volltext

150OAtezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study von Lee, K-H, Hsu, C-H, Lee, M S, Ryoo, B-Y, Verret, W, He, A R, Kwan, A, Liu, B, Iizuka, K, Stein, S

Volltext

SAXS Characterization of Nanochannels in Polymer-Derived SiC Fibers von Cheng, Hai Feng, Li, Xiao Dong, Chu, Zeng Yong, Wang, Jun, He, Rong An

Volltext

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study von He, A R, Weiss, G J, Falchook, G, Yee, N S, Gil-Martin, M, Shahda, S, Moreno, V, Brana, I, Crittenden, M, Formenti, S, Al-Rajabi, R, Papadopoulos, K P, Pishvaian, M J, Stankevich, E, Feng, M, Li, J, Mathias, M, Kroog, G, Lowy, I, Fury, M G

Volltext

Research on causes and mitigation measures of bright band on hot rolled strip von Guo, D. F., He, A. R., Shao, J.

Volltext

A phase II study of lapatinib and capecitabine in second line treatment of locally advanced/metastatic pancreatic cancer von He, A. R., Hwang, J. J., Marshall, J., Pishvaian, M., Slack, R., Weiner, L. M., Wellstein, A.

Volltext

A phase II study of the PARP inhibitor ABT-888 plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer von Pishvaian, M. J., Slack, R., Witkiewicz, A., He, A. R., Hwang, J. J., Hankin, A., Dorsch-Vogel, K., Kuda, D., McAndrew, T., Weiner, L. M., Marshall, J., Brody, J. R.

Volltext

A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer von Pishvaian, M. J., Slack, R., Witkiewicz, A., He, A. R., Hwang, J. J., Hankin, A., Ley, L., Apte, S. K., Littman, S. J., Weiner, L. M., Marshall, J., Brody, J. R.

Volltext

A phase I study of an oral formulation of ixabepilone (ixa) in patients with advanced cancer von He, A. R., Kunz, P. L., Pishvaian, M. J., Colevas, A. D., Hwang, J. J., Clemens, P. L., Messina, M., Kaleta, R., Abrahao, F., Sikic, B. I.

Volltext